Role of Individual Methionines in the Fibrillation of Methionine-Oxidized α-Synuclein

Biochemistry

Volumn 43, Issue 15, 2004, Pages 4621-4633

  Hokenson, Mark J ^a   Uversky, Vladimir N ^a   Goers, John ^a,b   Yamin, Ghiam ^a   Munishkina, Larissa A ^a   Fink, Anthony L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA POLYTECHNIC STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; DISEASES; NEUROLOGY; OXIDATION; PROTEINS; SUBSTITUTION REACTIONS; ZINC;

METHIONINE RESIDUES; NEURONS; OXIDATION INDUCED INHIBITION; OXIDATIVE STRESS;

BIOCHEMICAL ENGINEERING;

ALPHA SYNUCLEIN; LEUCINE; METHIONINE; OLIGOMER; SULFOXIDE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; HUMAN; IMAGE ANALYSIS; KINETICS; MORPHOLOGY; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REACTION ANALYSIS; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; AMINO ACID SUBSTITUTION; CIRCULAR DICHROISM; FLUORESCENCE POLARIZATION; HUMANS; LEUCINE; LIGHT; METHIONINE; MUTAGENESIS, SITE-DIRECTED; NERVE TISSUE PROTEINS; OXIDATION-REDUCTION; PROTEIN STRUCTURE, SECONDARY; SCATTERING, RADIATION; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SYNUCLEINS; ZINC;

EID: 9144274018     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi049979h     Document Type: Article

References (89)

1. Maroteaux, L., Campanelli, J. T., and Scheller, R. H. (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal, J. Neurosci. 8, 2804-2815.
2. Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., de Silva, H. A., Kittel, A., and Saitoh, T. (1995) The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system, Neuron 14, 467-475.
3. Weinreb, P. H., Zhen, W. G., Poon, A. W., Conway, K. A., and Lansbury, P. T., Jr. (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded, Biochemistry 35, 13709-13715.
4. Uversky, V. N., Li, J., and Fink, A. L. (2001) Evidence for a partially folded intermediate in alpha-synuclein fibril formation, J. Biol. Chem. 276, 10737-10744.
5. Uversky, V. N., Gillespie, J. R., and Fink, A. L. (2000) Why are "natively unfolded" proteins unstructured under physiologic conditions?, Proteins 41, 415-427.
6. Goedert, M. (2001) Parkinson's disease and other alpha-synucleinopathies, Clin. Chem. Lab. Med. 39, 308-312.
7. Trojanowski, J. Q., and Lee, V. M. (2003) Parkinson's disease and related alpha-synucleinopathies are brain amyloidoses, Ann. N.Y. Acad. Sci. 991, 107-110.
8. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997) Alpha-synuclein in Lewy bodies, Nature 388, 839-840.
9. Lewy, F. H. (1912) in Handbuch der Neurologie (Lewandowski, M., Ed.) pp 920-933, Springer, Berlin.
10. Forno, L. S. (1996) Neuropathology of Parkinson's disease, J. Neuropathol. Exp. Neurol. 55, 259-272.
11. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., Golbe, L. I., and Nussbaum, R. L. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease, Science 276, 2045-2047.
12. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J. T., Schols, L., and Riess, O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease, Nat. Genet. 18, 106-108.
13. Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A., Hanson, M., Maraganore, D., Adler, C., Cookson, M. R., Muenter, M., Baptista, M., Miller, D., Blancato, J., Hardy, J., and Gwinn-Hardy, K. (2003) alpha-Synuclein locus triplication causes Parkinson's disease, Science 302, 841.
14. Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., and Mucke, L. (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders, Science 287, 1265-1269.
15. Feany, M. B., and Bender, W. W. (2000) A Drosophila model of Parkinson's disease, Nature 404, 394-398.
16. Conway, K. A., Harper, J. D., and Lansbury, P. T. (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease, Nat. Med. 4, 1318-1320.
17. Conway, K. A., Lee, S. J., Rochet, J. C., Ding, T. T., Williamson, R. E., and Lansbury, P. T., Jr. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy, Proc. Natl. Acad. Sci. U.S.A. 97, 571-576.
18. Crowther, R. A., Jakes, R., Spillantini, M. G., and Goedert, M. (1998) Synthetic filaments assembled from C-terminally truncated alpha-synuclein, FEBS Lett. 436, 309-312.
19. Giasson, B. I., Uryu, K., Trojanowski, J. Q., and Lee, V. M. Y. (1999) Mutant and wild-type human alpha-synuclein assemble into elongated filaments with distinct morphologies in vitro, J. Biol. Chem. 274, 7619-7622.
20. Wood, S. J., Wypych, J., Steavenson, S., Louis, J. C., Citron, M., and Biere, A. L. (1999) Alpha-synuclein fibrillogenesis is nucleation-dependent, J. Biol. Chem. 274, 19509-19512.
21. Serpell, L. C., Berriman, J., Jakes, R., Goedert, M., and Crowther, R. A. (2000) Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation, Proc. Natl. Acad. Sci. U.S.A. 97, 4897-4902.
22. Stadtman, E. R., Oliver, C. N., Starke-Reed, P. E., and Rhee, S. G. (1993) Age-related oxidation reaction in proteins, Toxicol. Ind. Health 9, 187-196.
23. Stadtman, E. R., and Berlett, B. S. (1997) Reactive oxygen-mediated protein oxidation in aging and disease, Chem. Res. Toxicol. 10, 485-494.
24. Leeuwenburgh, C., Hansen, P., Shaish, A., Holloszy, J. O., and Heinecke, J. W. (1998) Markers of protein oxidation by hydroxyl radical and reactive nitrogen species in tissues of aging rats, Am. J. Physiol. 43, R453-R461.
25. Butterfield, D. A., Howard, B., Yatin, S., Koppal, T., Drake, J., Hensley, K., Aksenov, M., Aksenova, M., Subramaniam, R., Varadarajan, S., Harris-White, M. E., Pedigo, N. W., Jr., and Carney, J. M. (1999) Elevated oxidative stress in models of normal brain aging and Alzheimer's disease, Life Sci. 65, 1883-1892.
26. Smith, C. D., Carney, J. M., Starke-Reed, P. E., Oliver, C. N., Stadtman, E. R., Floyd, R. A., and Markesbery, W. R. (1991) Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease, Proc. Natl. Acad. Sci U.S.A. 88, 10540-10543.
27. Aksenova, M. V., Aksenov, M. Y., Payne, R. M., Trojanowski, J. Q., Schmidt, M. L., Carney, J. M., Butterfield, D. A., and Markesbery, W. R. (1999) Oxidation of cytosolic proteins and expression of creatine kinase BB in frontal lobe in different neurodegenerative disorders, Dementia Geriatr. Cognit. Disord. 10, 158-165.
28. Markesbery, W. R., and Carney, J. M. (1999) Oxidative alterations in Alzheimer's disease, Brain Pathol. 9, 133-146.
29. Duda, J. E., Giasson, B. I., Chen, Q., Gur, T. L., Hurtig, H. I., Stern, M. B., Gollomp, S. M., Ischiropoulos, H., Lee, V. M., and Trojanowski, J. Q. (2000) Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies, Am. J. Pathol. 157, 1439-1445.
30. Jenner, P., Dexter, D. T., Sian, J., Schapira, A. H., and Marsden, C. D. (1992) Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group, Ann. Neurol. 32 (Suppl.), S82-S87.
31. Jenner, P. (2003) Oxidative stress in Parkinson's disease, Ann. Neurol. 53 (Suppl. 3), S26-S36.
32. Lyras, L., Perry, R. H., Perry, E. K., Ince, P. G., Jenner, A., Jenner, P., and Halliwell, B. (1998) Oxidative damage to proteins, lipids, and DNA in cortical brain regions from patients with dementia with Lewy bodies, J. Neurochem. 71, 302-312.
33. Browne, S. E., Ferrante, R. J., and Beal, M. F. (1999) Oxidative stress in Huntington's disease, Brain Pathol. 9, 147-163.
34. Cookson, M. R., and Shaw, P. J. (1999) Oxidative stress and motor neurone disease, Brain Pathol. 9, 165-186.
35. Vogt, W. (1995) Oxidation of methionyl residues in proteins: tools, targets, and reversal, Free Radical Biol. Med. 18, 93-105.
36. Moskovitz, J., Weissbach, H., and Brot, N. (1996) Cloning the expression of a mammalian gene involved in the reduction of methionine sulfoxide residues in proteins, Proc. Natl. Acad. Sci. U.S.A. 93, 2095-2099.
37. Sun, H., Gao, J., Ferrington, D. A., Biesiada, H., Williams, T. D., and Squier, T. C. (1999) Repair of oxidized calmodulin by methionine sulfoxide reductase restores ability to activate the plasma membrane Ca-ATPase, Biochemistry 38, 105-112.
38. Levine, R. L., Mosoni, L., Berlett, B. S., and Stadtman, E. R. (1996) Methionine residues as endogenous antioxidants in proteins, Proc. Natl. Acad. Sci. U.S.A. 93, 15036-15040.
39. Uversky, V. N., Li, J., Bower, K., and Fink, A. L. (2002) Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: Implications for Parkinson's disease, Neurotoxicology 23, 527-536.
40. Uversky, V. N., and Fink, A. L. (2002) Biophysical properties of human alpha-synuclein and its role in Parkinson's disease, in Recent Research Developments in Proteins (Pandalai, S. G., Ed.) pp 153-186, Transworld Research Network, Kerala, India.
41. Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E. R., and Mizuno, Y. (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease, Proc. Natl. Acad. Sci. U.S.A. 93, 2696-2701.
42. Good, P. F., Hsu, A., Werner, P., Perl, D. P., and Olanow, C. W. (1998) Protein nitration in Parkinson's disease, J Neuropathol. Exp. Neurol. 57, 338-342.
43. Giasson, B. I., Duda, J. E., Murray, I. V., Chen, Q., Souza, J. M., Hurtig, H. I., Ischiropoulos, H., Trojanowski, J. Q., and Lee, V. M. (2000) Oxidative damage linked to neurodegeneration by selective alpha- synuclein nitration in synucleinopathy lesions, Science 290, 985-989.
44. Paik, S. R., Shin, H. J., and Lee, J. H. (2000) Metal-catalyzed oxidation of alpha-synuclein in the presence of copper(II) and hydrogen peroxide, Arch. Biochem. Biophys. 378, 269-277.
45. Conway, K. A., Rochet, J. C., Bieganski, R. M., and Lansbury, P. T., Jr. (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct, Science 294, 1346-1349.
46. Uversky, V. N., Yamin, G., Souillac, P. O., Goers, J., Glaser, C. B., and Fink, A. L. (2002) Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro, FEBS Lett. 517, 239-244.
47. Oberg, K. A., and Fink, A. L. (1998) A new attenuated total reflectance Fourier transform infrared spectroscopy method for the study of proteins in solution, Anal. Biochem. 256, 92-106.
48. Nielsen, L., Khurana, R., Coats, A., Frokjaer, S., Brange, J., Vyas, S., Uversky, V. N., and Fink, A. L. (2001) Effect of environmental factors on the kinetics of insulin fibril formation: Elucidation of the molecular mechanism, Biochemistry 40, 6036-6046.
49. Li, J., Uversky, V. N., and Fink, A. L. (2001) Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein, Biochemistry 40, 11604-11613.
50. Uversky, V. N., Li, J., Souillac, P., Jakes, R., Goedert, M., and Fink, A. L. (2002) Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins, J. Biol. Chem. 277, 11970-11978.
51. Munishkina, L. A., Phelan, C., Uversky, V. N., and Fink, A. L. (2003) Conformational behavior and aggregation of alpha-synuclein in organic solvents: Modeling the effects of membranes, Biochemistry 42, 2720-2730.
52. Naiki, H., Higuchi, K., Matsushima, K., Shimada, A., Chen, W. H., Hosokawa, M., and Takeda, T. (1990) Fluorometric examination of tissue amyloid fibrils in murine senile amyloidosis: use of the fluorescent indicator, thioflavine T, Lab. Invest. 62, 768-773.
53. Naiki, H., Higuchi, K., Hosokawa, M., and Takeda, T. (1989) Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T, Anal. Biochem. 177, 244-249.
54. Naiki, H., Higuchi, K., Nakakuki, K., and Takeda, T. (1991) Kinetic analysis of amyloid fibril polymerization in vitro, Lab. Invest. 65, 104-110.
55. Kim, Y. H., Berry, A. H., Spencer, D. S., and Stites, W. E. (2001) Comparing the effect on protein stability of methionine oxidation versus mutagenesis: steps toward engineering oxidative resistance in proteins, Protein Eng. 14, 343-347.
56. Uversky, V. N., Li, J., Souillac, P., Jakes, R., Goedert, M., and Fink, A. L. (2002) Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins, J. Biol. Chem. 277, 11970-11978.
57. Yamin, G., Glaser, C. B., Uversky, V. N., and Fink, A. L. (2003) Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein, J. Biol. Chem 278, 27630-27635.
58. Uversky, V. N., Karnoup, A. S., Khurana, R., Segel, D. J., Doniach, S., and Fink, A. L. (1999) Association of partially folded intermediates of staphylococcal nuclease induces structure and stability, Protein Sci. 8, 161-173.
59. Kuznetsova, I. M., Biktashev, A. G., Khaitlina, S. Y., Vassilenko, K. S., Turoverov, K. K., and Uversky, V. N. (1999) Effect of self-association on the structural organization of partially folded proteins: inactivated actin, Biophys. J. 77, 2788-2800.
60. Uversky, V. N., Li, J., Souillac, P., Jakes, R., Goedert, M., and Fink, A. L. (2002) Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins, J. Biol. Chem. 277, 11970-11978.
61. Kyte, J., and Doolittle, R. F. (1982) A simple method for displaying the hydropathic character of a protein, J. Mol. Biol. 157, 105-132.
62. Fink, A. L., Seshadri, S., Khurana, R., and Oberg, K. A. (1999) in Infrared Analysis of Peptides and Proteins (Singh, B. R., Ed.) pp 132-144, American Chemical Society, Washington, DC.
63. Oberg, K., Chrunyk, B. A., Wetzel, R., and Fink, A. L. (1994) Nativelike secondary structure in interleukin-1 beta inclusion bodies by attenuated total reflectance FTIR, Biochemistry 33, 2628-2634.
64. Ismail, A. A., Mantsch, H. H., and Wong, P. T. T. (1992) Aggregation of chymotrypsinogen-portrait by infrared spectroscopy, Biochim. Biophys. Acta 1121, 183-188.
65. Przybycien, T. M., Dunn, J. P., Valax, P., and Georgiou, G. (1994) Secondary structure characterization of beta-lactamase inclusion bodies, Protein Eng. 7, 131-136.
66. Kendrick, B. S., Cleland, J. L., Lam, X., Nguyen, T., Randolph, T. W., Manning, M. C., and Carpenter, J. F. (1998) Aggregation of recombinant human interferon gamma: kinetics and structural transitions, J. Pharm. Sci. 87, 1069-1076.
67. Clark, A. H., Saunderson, D. H., and Suggett, A. (1981) Infrared and laser-Raman spectroscopic studies of thermally-induced globular protein gels, Int. J. Pept. Protein Res. 17, 353-364.
68. Fink, A. L. (1998) Protein aggregation: folding aggregates, inclusion bodies and amyloid, Folding Des. 3, 9-15.
69. Nielsen, L., Frokjaer, S., Carpenter, J. F., and Brange, J. (2001) Studies of the structure of insulin fibrils by Fourier transform infrared (FTIR) spectroscopy and electron microscopy, J. Pharm. Sci. 90, 29-37.
70. Ueda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., Otero, D. A., Kondo, J., Ihara, Y., and Saitoh, T. (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease, Proc. Natl. Acad. Sci. U.S.A. 90, 11282-11286.
71. Han, H., Weinreb, P. H., and Lansbury, P. T., Jr. (1995) The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease?, Chem. Biol. 2, 163-169.
72. Hashimoto, M., Rockenstein, E., Mante, M., Mallory, M., and Masliah, E. (2001) beta-Synuclein inhibits alpha-synuclein aggregation. A possible role as an anti-parkinsonian factor, Neuron 32, 213-223.
73. Uversky, V. N., Li, J., Souillac, P., Millett, I. S., Doniach, S., Jakes, R., Goedert, M., and Fink, A. L. (2002) Biophysical properties of the synucleins and their propensities to fibrillate-Inhibition of alpha-synuclein assembly by beta- and gamma-synucleins, J. Biol. Chem. 277, 11970-11978.
74. Park, J. Y., and Lansbury, P. T. (2003) beta-synuclein inhibits formation of alpha-synuclein protofibrils: A possible therapeutic strategy against Parkinson's disease, Biochemistry 42, 3696-3700.
75. Giasson, B. I., Murray, I. V., Trojanowski, J. Q., and Lee, V. M. (2001) A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly, J. Biol. Chem. 276, 2380-2386.
76. Bodles, A. M., Guthrie, D. J., Greer, B., and Irvine, G. B. (2001) Identification of the region of non-Abeta component (NAC) of Alzheimer's disease amyloid responsible for its aggregation and toxicity, J. Neurochem. 78, 384-395.
77. Bodles, A. M., Guthrie, D. J., Harriott, P., Campbell, P., and Irvine, G. B. (2000) Toxicity of non-abeta component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of beta-sheet structure and fibrils, Eur. J. Biochem. 267, 2186-2194.
78. Irvine, G. B., El Agnaf, O. M., Bodles, A. M., Guthrie, D. J., and Harriott, P. (1998) Studies on the aggregation and secondary structure of peptides derived from non-A beta component of Alzheimer's disease amyloid, Biochem. Soc. Trans. 26, S36.
79. El Agnaf, O. M., Bodles, A. M., Guthrie, D. J., Harriott, P., and Irvine, G. B. (1998) The N-terminal region of non-A beta component of Alzheimer's disease amyloid is responsible for its tendency to assume beta-sheet and aggregate to form fibrils, Eur. J. Biochem. 258, 157-163.
80. Clayton, D. F., and George, J. M. (1998) The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease, Trends Neurosci. 21, 249-254.
81. George, J. M., Jin, H., Woods, W. S., and Clayton, D. F. (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch, Neuron 15, 361-372.
82. Kessler, J. C., Rochet, J. C., and Lansbury, P. T. (2003) The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation, Biochemistry 42, 672-678.
83. Conway, K. A., Harper, J. D., and Lansbury, P. T., Jr. (2000) Fibrils formed in vitro from alfa-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid, Biochemistry 39, 2552-2563.
84. Narhi, L., Wood, S. J., Steavenson, S., Jiang, Y., Wu, G. M., Anafi, D., Kaufman, S. A., Martin, F., Sitney, K., Denis, P., Louis, J. C., Wypych, J., Biere, A. L., and Citron, M. (1999) Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation, J. Biol. Chem. 274, 9843-9846.
85. Li, J., Uversky, V. N., and Fink, A. L. (2002) Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T, Neurotoxicology 23, 553-567.
86. Uversky, V. N., and Fink, A. L. (2002) Amino acid determinants of alpha-synuclein aggregation: putting together pieces of the puzzle, FEBS Lett. 522, 9-13.
87. Trojanowski, J. Q., and Lee, V. M. (2000) "Fatal attractions" of proteins. A comprehensive hypothetical mechanism underlying Alzheimer's disease and other neurodegenerative disorders, Ann. N.Y. Acad. Sci. 924, 62-67.
88. Hou, L., Kang, I., Marchant, R. E., and Zagorski, M. G. (2002) Methionine 35 oxidation reduces fibril assembly of the amyloid abeta-(1-42) peptide of Alzheimer's disease, J. Biol. Chem. 277, 40173-40176.
89. Hou, L., Shao, H., Zhang, Y., Li, H., Menon, N. K., Neuhaus, E. B., Brewer, J. M., Byeon, I.-J. L., Ray, D. G., Vitek, M. P., Iwashita, T., Makula, R. A., Przybyla, A. B., and Zagorski, M. G. (2004) Solution NMR studies of the amyloid beta(1-40) and amyloid beta(1-42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation, J. Am. Chem. Soc. (in press).